Seno

Xinuo Technology Technology Limited Company d. b. a. , Seno, based in China, specializes in manufacturing nicotine oral films, providing a modern alternative to traditional nicotine consumption methods.

The company leverages advanced biomedical technologies to enhance user experience and promote healthier lifestyle choices. Founded in 2024, Seno operates out of Guangdong, China, focusing on innovative nicotine oral film solutions. The company was Co-founded by Jason Zhao. In November 2025, Seno raised USD 700,000 in pre-seed funding.

Seno specializes in the manufacturing of nicotine oral films, designed to offer a modern and healthier alternative to traditional nicotine consumption methods. Utilizing advanced biomedical technologies, these films cater to a diverse client base across North America and Europe, where the demand for innovative nicotine products is rising. The films provide a discreet approach to managing nicotine intake, appealing to current users seeking alternatives and individuals interested in harm-reduction solutions. Seno generates revenue through direct sales of its nicotine oral films to consumers and retail partners.

Its sales structure includes B2B relationships with wholesalers, allowing for broader market distribution. The flagship product line includes nicotine oral films available in various flavors and strengths to meet a wide audience's needs. This pricing strategy ensures accessibility and supports revenue growth through consistent product sales and solid partnerships in the health and wellness sectors. The company will use this November 2025 funding to expand research and development, support testing and validation activities, and enhance quality and safety systems.